The FDA’s approval was based on part one of a two-part study that showed Wegovy helped more patients with a liver condition known as MASH improve the organ’s condition, compared to a placebo.

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition known as metabolic dysfunction-associated steatohepatitis.

The decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a progressive liver condition that affects around 5% of adults in the U.S., according to the American Liver Foundation.

The approval is for use alongside a reduced-calorie diet and increased physical activity.

The FDA’s approval was based on part one of a two-part study that showed Wegovy helped more pat

See Full Page